Aug. 21 at 8:51 PM
$LENZ @Nicothebest Nick, thanks for the detailed email reply regarding launch in Europe. I won’t turn this into five separate public debates, but on one point I largely agree with you: LENZ has done a poor job of managing the capital-market narrative.
I raised essentially the same issue directly with Dan before. Eef can explain the commercial logic, but LENZ still fails to translate it into the KPIs and financial bridge investors need: absolute Rx progression, cohorts, channel productivity, patient-to-pack data, SG&A/cash burn and the path to operating leverage.
That vacuum is now being filled by a very simple narrative: slow launch → cash burn → uncertain profitability →
$7.
So yes: on communication, Dan has not made a good enough case. Where I disagree is in treating weak communication as proof that every other negative conclusion must also be right.
